HK Stock Market Move | CSPC Pharma (01093) rises by nearly 5% again. The company's collaboration with AstraZeneca is further upgraded, potentially accelerating the global layout of long-acting peptide drugs.

CSPC PHARMA (01093) rose nearly 5% again, as of press time, up 4.7% to HK$10.24, with a turnover of HK$486 million. On the news front, CSPC PHARMA recently announced a strategic cooperation and licensing agreement with AstraZeneca for the development of innovative long-acting peptide drugs. Northeast believes that the transaction amount of this BD with AstraZeneca exceeded expectations, and the high upfront payment fully demonstrates AstraZeneca's high recognition and long-term optimism for the company's long-acting peptide and AI pharmaceutical technology platform. This cooperation also signifies an upgrade in the company's collaboration with AstraZeneca, potentially accelerating the global deployment of the company's long-acting peptide drugs. The firm believes that CSPC PHARMA's cooperation with AstraZeneca this time revolves around the company's proprietary sustained-release drug delivery technology platform and peptide drug AI discovery platform. The company's long-acting technology can achieve sustained release of peptide drugs. At the same time, the company's peptide drug AI discovery platform can quickly design and screen candidate molecules for drug targets, and systematically optimize them in terms of drug efficacy, selectivity, and signal bias.